ClinicalTrials.gg
RecruitingNCT07493096GEN-HOPEUpdated Mar 25, 2026

Intensive Multimodal Neurorehabilitation Targeting Neuroplasticity in Pediatric Neurodevelopmental and Chromosomal Disorders

An observational study in Neurodevelopmental Disorders, Neurodevelopmental Disorders (NDD) and Neurodevelopmental Disorders and Developmental Abnormalities, sponsored by Healing Hope International. Recruiting at 1 site in United States. Open to participants aged 4 Years to 12 Years. Per ClinicalTrials.gov, last updated 2026-03-25.

Sponsored by Healing Hope International · Observational

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.
Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
100
Ages
4 Years to 12 Years
Sex
All
01

Study summary

This observational study evaluates functional and developmental outcomes in pediatric participants undergoing a two week intensive multimodal neurorehabilitation program. The program is designed for children with neurodevelopmental disorders, including but not limited to cerebral palsy, autism spectrum disorder, developmental delay, hypoxic ischemic encephalopathy (HIE), and chromosomal or genetic abnormalities.

Participants receive individualized therapy sessions for approximately 2.5 hours per day over a two week period. The intervention is not standardized but is tailored to each child's specific needs and may include components such as sensory integration, motor planning, reflex integration, oculomotor training, executive functioning activities, communication support, and other brain based therapeutic approaches.

The purpose of this study is to observe changes in functional abilities, including attention, motor coordination, emotional regulation, communication, and activities of daily living. Outcomes are assessed using clinician observation and parent reported changes before and after the intensive program, with limited follow-up when available.

This study does not assign participants to a specific treatment as part of a research protocol. Instead, it collects real world data from children already participating in a clinical therapy program to better understand potential benefits of intensive, individualized neurorehabilitation approaches.

Read the detailed description

Children with neurodevelopmental disorders often present with complex impairments affecting motor function, sensory processing, communication, attention, emotional regulation, and daily living skills. These conditions may arise from acquired neurologic injury (such as hypoxic ischemic encephalopathy or traumatic brain injury) or from genetic and chromosomal abnormalities (such as Down syndrome, Rett syndrome, or other genomic disorders).

Traditional therapy models delivered at low frequency may not fully address the intensity required to drive meaningful neuroplastic change. Intensive, high frequency, and multimodal rehabilitation approaches have been proposed as a strategy to enhance neural adaptation by increasing repetition, engagement, and cross-modal stimulation within a short time period.

This observational study is designed to systematically characterize real world outcomes associated with a two week pediatric intensive therapy model that integrates multiple therapeutic modalities tailored to the individual child.

This is a prospective observational study of pediatric participants enrolled in an intensive therapy program. No randomization or experimental intervention is introduced as part of the study. All therapies are delivered as part of routine clinical care.

Participants attend therapy sessions for approximately 2.5 hours per day, 5 days per week, for 2 consecutive weeks.

Therapy is individualized and may include a combination of:

  • Sensory integration techniques
  • Motor planning and coordination activities
  • Reflex integration exercises
  • Oculomotor and visual processing training
  • Auditory processing activities
  • Executive functioning tasks
  • Communication support strategies
  • Emotional regulation training
  • Brain based and neurodevelopmental exercises

Additional modalities such as vibration, tactile stimulation, and photobiomodulation may be used at the discretion of the treating clinician.

This study aims to generate real world evidence on the potential benefits of intensive, individualized, multimodal neurorehabilitation in children with complex neurodevelopmental conditions, including those with genetic and chromosomal etiologies. Findings may inform future controlled studies and help guide clinical decision making for therapy intensity and program design.

02

Conditions studied

  • Neurodevelopmental Disorders
  • Neurodevelopmental Disorders (NDD)
  • Neurodevelopmental Disorders and Developmental Abnormalities
  • Developmental Delay (Disorder)
  • Cerebral Palsy (CP)
  • Cerebral Palsy Hemiparetic Cerebral Palsy Spasticity Gait Disorders, Neurologic Postural Balance Impairment
  • Cerebral Palsy Infantile
  • Cerebral Palsy Spastic Hemiplegic
  • Cerebral Palsy, Dyskinetic
  • Autism Spectrum Disorder
  • Autism Spectrum Disorder (ASD
  • Hypoxic Ischemic Encephalopathy
  • Hypoxic Ischemic Encephalopathy (HIE)
  • Traumatic Brain Injury (TBI)
  • Sensory Processing Disorder
  • Chromosomal Abnormalities
  • Genetic Disorders
  • Down Syndrome (Trisomy 21)
  • Fragile X Syndrome (FXS)
  • RETT Syndrome With Proven MECP2 Mutation
  • Williams Syndrome
  • 22q11.2 Deletion Syndrome
  • Sensorimotor Integration

Keywords

  • Photobiomodulation
  • Low-Level Laser Therapy
  • Vibration Therapy
  • Tactile Stimulation
  • Cognitive Training
  • Behavioral Therapy
  • Intensive Therapy
  • Pediatric Neurorehabilitation
  • Multimodal Therapy
  • Neuroplasticity
  • Sensory Integration
  • Reflex Integration
  • Motor Planning
  • Executive Function
  • Emotional Regulation
  • Functional Outcomes
  • Activities of Daily Living
  • High Frequency Therapy
  • Neurodevelopmental Disorders
  • Rehabilitation
  • Child Development Disorders
  • Occupational Therapy
  • Physical Therapy Modalities
  • Early Intervention
  • Cognitive Therapy
03

In context

Neurodevelopmental Disorders

352 studies on the registry are indexed under Neurodevelopmental Disorders; 141 are open to participants now.

This study's planned enrollment of 100 is below the median of 200 across 133 observational studies indexed under Neurodevelopmental Disorders.

Browse Neurodevelopmental Disorders studies →

Lead sponsor

Healing Hope International is the lead sponsor of 6 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
4 Years to 12 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population consists of pediatric participants enrolled in a two week intensive therapy program conducted in a clinical pediatric neurodevelopmental rehabilitation setting. Participants are drawn from a real world clinical population referred for intensive therapy due to functional impairments in motor, sensory, cognitive, communication, and/or regulatory domains.

Participants represent a heterogeneous group of children with neurodevelopmental, neurologic, and genetic conditions, including those with acquired brain injury, developmental disorders, and chromosomal abnormalities. Children are referred through clinical providers or caregiver self referral and participate as part of routine care rather than assignment to a research intervention.

This population reflects a community based sample of children receiving individualized, high frequency, multimodal therapy in an outpatient intensive program.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Pediatric participants between approximately 4 and 12 years of age at the time of enrollment.
  • Diagnosed with or presenting with neurodevelopmental, neurologic, or genetic conditions, including but not limited to:

    • cerebral palsy
    • autism spectrum disorder
    • developmental delay
    • hypoxic ischemic encephalopathy (HIE)
    • traumatic brain injury
    • sensory processing disorder
    • chromosomal or genetic abnormalities
    • Demonstrate functional impairments in one or more neurodevelopmental domains, including:
  • motor coordination or motor planning
  • sensory processing
  • attention or executive functioning
  • oculomotor or visual processing
  • communication
  • emotional or behavioral regulation
  • activities of daily living
  • Enrolled in and able to participate in a two-week intensive therapy program consisting of approximately 2.5 hours per day/ 5 days per week

    • Able to complete baseline and post-program clinical assessment using clinician-observed or caregiver-reported measures.
    • Parent or legal guardian able to provide and participate in reporting functional outcomes when applicable.

Exclusion criteria

Exclusion Criteria:

  • Medical instability or acute medical condition that would prevent safe participation in an intensive therapy program.
  • Severe uncontrolled seizure activity or other neurologic condition that would interfere with participation in structured therapeutic activities, as determined by the treating clinician.
  • Behavioral or psychological conditions that would prevent safe engagement in the therapy environment despite appropriate support.
  • Inability to attend or complete the full two-week intensive program.
  • Lack of sufficient baseline or post-intervention data to assess change in functional performance.
  • Concurrent participation in another structured intervention or clinical study that would confound interpretation of functional outcomes, at the discretion of the investigator.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
100 participants (estimated)
Patient registry
No

Groups and cohorts

  • Pediatric Intensive Multimodal Neurorehabilitation Cohort

    This cohort includes pediatric participants with neurodevelopmental disorders, including cerebral palsy, autism spectrum disorder, developmental delay, hypoxic ischemic encephalopathy, traumatic brain injury, and genetic or chromosomal abnormalities, who are enrolled in a two-week intensive multimodal neurorehabilitation program. Participants receive individualized therapy for approximately 2.5 hours per day, 5 days per week, for 2 consecutive weeks. The intervention is not standardized and is tailored to each participant's clinical needs. Therapy may include sensory integration, motor planning, reflex integration, oculomotor training, auditory processing activities, executive functioning tasks, communication support, emotional regulation strategies, and other neurodevelopmental approaches. Additional modalities such as tactile stimulation, vibration, and photobiomodulation may be utilized at the discretion of the treating clinician.

06

What researchers measure

Primary outcomes

  1. Change in Clinician Assessed Functional Neurodevelopmental Performance

    Within participant change from baseline to completion of the 2 week intensive program in individualized clinician assessed neurodevelopmental performance domains used in routine care. Measures may include neural timing accuracy in milliseconds relative to metronome paced motor tasks, oculomotor performance scored by saccadic eye movements and horizontal pursuits, primitive reflex integration scored on a 0-5 scale, processing speed/visual scanning completion time, bilateral coordination, crossing midline, sustained attention duration, tactile or stimulation tolerance, executive functioning, emotional regulation, communication intent, and participation in non preferred activities. Each participant is assessed only on domains relevant to their presentation, consistent with the source document's individualized assessment model.

    Time frame: Baseline to end of 2 week intensive program

Secondary outcomes

  1. Change in Neural Timing Accuracy

    Change in neural timing performance during metronome paced motor sequencing tasks, recorded as milliseconds from target rhythm and/or number of steps completed at target accuracy.

    Time frame: Baseline to end of 2 week intensive program

  2. Change in Oculomotor Control

    Change in oculomotor performance assessed by clinician-scored saccadic eye movements and horizontal pursuits, recorded as number correct out of 16 when applicable.

    Time frame: Baseline to end of 2 week intensive program

  3. Change in Primitive Reflex Persistence

    Change in primitive reflex persistence or integration assessed by clinician rating on a 0 to 5 scale and/or reflex status. Reflexes assessed may include TLR, ATNR, STNR, MORO, Rooting, Palmar, Spinal Galant, Spinal Perez, and Babkin, depending on participant presentation.

    Time frame: Baseline to end of 2 week intensive program

  4. Change in Processing Speed and Visual Scanning Time

    Change in processing speed and visual scanning measured by time to complete structured scanning tasks. Depending on participant presentation, tasks may include color, number, word, color-word, 69 arrows, and BD69 scanning activities, as well as sorting number/shape/color. Lower completion time indicates improvement.

    Time frame: Baseline to end of 2-week intensive program

  5. Change in Bilateral Word Taps and Cross Midline Performance

    Change in bilateral word tap performance measured by time to complete assigned 100 series or 200 series pages, with notation of cueing needs for crossing midline when applicable.

    Time frame: Baseline to end of 2-week intensive program

  6. Change in Attention, Activity Tolerance, and Participation in Non Preferred Activities

    Change in ability to sustain engagement in therapeutic activity and participate in non preferred tasks, measured by clinician observation using duration in minutes, percentage of participation, and/or required level of assistance.

    Time frame: Baseline to end of 2 week intensive program

  7. Change in Emotional Self Regulation

    Change in emotional regulation or self regulation assessed by clinician rated delay severity, ability to identify feelings, behavioral response during challenge, and/or level of assistance required for regulation and transitions.

    Time frame: Baseline to end of 2 week intensive program

  8. Parent Reported Functional Carryover and Retention of Gains

    Parent or caregiver reported change in daily functioning after the intensive, including independence in morning or bedtime routines, self care, mealtime behavior, reading speed, communication, community outings, emotional regulation, problem solving, and retention of gains.

    Time frame: Up to 4 weeks after completion of the intensive program

07

Study locations

1 of 1 sites recruiting
  • Ability and Beyond
    The Woodlands, Texas 77380, United States
    Recruiting
08

References and documents

Publications

  • Ward, R., Reynolds, J., & Marshall, A. (2019). Intensity of therapy and functional outcomes in children receiving rehabilitation: A systematic review. Developmental Medicine & Child Neurology, 61(8), 906-915. https://doi.org/10.1111/dmcn.14190
  • Sakzewski L, Ziviani J, Boyd RN. Delivering evidence-based upper limb rehabilitation for children with cerebral palsy: barriers and enablers identified by three pediatric teams. Phys Occup Ther Pediatr. 2014 Nov;34(4):368-83. doi: 10.3109/01942638.2013.861890. Epub 2013 Dec 4. PubMed 24303800 ↗
  • Novak I, Honan I. Effectiveness of paediatric occupational therapy for children with disabilities: A systematic review. Aust Occup Ther J. 2019 Jun;66(3):258-273. doi: 10.1111/1440-1630.12573. Epub 2019 Apr 10. PubMed 30968419 ↗
  • Bower, E., McLellan, D. L., Arney, J., & Campbell, M. J. (1996). A randomized controlled trial of different intensities of physiotherapy and constraint-induced movement therapy in children with cerebral palsy. BMJ, 312(7033), 1239-1243. https://doi.org/10.1136/bmj.312.7033.1239

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2026 (actual). Primary completion is estimated for Jan 2028, 22 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 19, 2026
First posted
Mar 25, 2026
StartActual
Mar 1, 2026
Primary completionEst.
Jan 1, 2028
CompletionEst.
Dec 30, 2036
Last update
Mar 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 25, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07493096
Lead sponsor
Healing Hope International
Responsible party
Sponsor
First posted
Mar 25, 2026
Start date
Mar 1, 2026
Primary completion
Jan 1, 2028 (estimated)
Completion
Dec 30, 2036 (estimated)
Last update
Mar 25, 2026

Study contacts

Genelle Mills, OTR/L
Contact
genelle@abilityandbeyond.com
(480) 620-4514
Tamara Tamas, MS RA
Contact
(863) 354- 5131
Dr. Tina Casoglos-Adamopoulos, OT, OTD, BCP
principal investigator · Board Certified Pediatric Therapist Executive Director Ability and Beyond Integrated Therapies

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion